Cog­ni­tion Ther­a­peu­tic­s' stock sinks on Phase 2 Alzheimer’s da­ta

New Alzheimer’s da­ta from Cog­ni­tion Ther­a­peu­tics ap­peared to show an ear­ly drug ef­fect, but one that less­ened over time.

Cog­ni­tion pre­sent­ed Phase 2 re­sults from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER